{"acquisitions":[],"changes":[],"country":"US","description":"Retro Biosciences develops therapeutics that extend healthy lifespan, with programs in autophagy, cellular reprogramming, and plasma fractions. The audience is patients with age-driven diseases and clinicians seeking interventions that target biological aging. Retro is funded in large part by Sam Altman's personal capital.","domain":"retro.bio","employees":null,"founded":2021,"fundingTotalQuarantined":false,"githubOrg":"retrobiosciences","githubStars":13,"industry":"unknown","industrySources":[],"investors":[],"lat":37.787936,"lng":-122.40752,"location":"San Francisco, US","multiples":[],"name":"Retro Biosciences","people":[],"revenues":[],"rounds":[{"amountQuarantined":false,"amountUsd":1000000000,"connectionsAmong":[],"currency":"USD","date":"2025-01-24","investments":[],"investors":[],"leadInvestor":null,"leadInvestors":[],"people":[],"slug":"retro-bio-2025-01-24-series-a","source":{"fact":"round","publisher":"techcrunch","retrievedAt":"2026-05-07","status":"attributed","url":null},"status":"attributed","type":"series-a","url":null}],"slug":"retro-bio","sources":[{"fact":"round","publisher":"techcrunch","retrievedAt":"2026-05-07","status":"attributed","url":null},{"fact":"existence","publisher":"retro.bio","retrievedAt":"2026-05-07","status":"self-reported","url":"https://retro.bio"},{"fact":"description","publisher":"retro.bio","retrievedAt":"2026-05-07","status":"self-reported","url":"https://retro.bio"}],"stage":"series-a","stockCard":{"asOf":"2026-11-09","facts":[],"generatedAt":"2026-11-09","state":"insufficient-evidence","tldr":[]},"techStack":["Vercel","Next.js","React"],"totalRaisedUsd":1180000000,"traction":[],"updatedAt":"2026-05-07","valuations":[]}